Tuberculosis treatment: dangerous regimens?
Rieder
H L
HL
The International Union Against Tuberculosis and Lung Disease, Paris, France.
Arnadottir
T
T
Trébucq
A
A
Enarson
D A
DA
D000995:Antitubercular Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013307:Streptomycin / Q000008:administration & dosage; D013828:Thioacetazone / Q000008:administration & dosage; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014944:World Health Organization
D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D013828:Thioacetazone; D007538:Isoniazid; D012293:Rifampin; C018421:rifapentine; D013307:Streptomycin